[HTML][HTML] Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer

J Breul, E Lundström, D Purcea, WP Venetz, P Cabri… - Advances in …, 2017 - Springer
Introduction Androgen deprivation therapy (ADT) is a mainstay of treatment against
advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone …

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

J Breul, E Lundström, D Purcea, WP Venetz, P Cabri… - Advances in …, 2016 - infona.pl
Introduction Androgen deprivation therapy (ADT) is a mainstay of treatment against
advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone …

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.

J Breul, E Lundström, D Purcea, WP Venetz… - Advances in …, 2016 - europepmc.org
Methods Data of 920 male patients with PC enrolled in 9 prospective studies using
testosterone serum concentrations as primary endpoint were pooled. Patients aged 42-96 …

[HTML][HTML] Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

J Breul, E Lundström, D Purcea, WP Venetz… - Advances in …, 2017 - ncbi.nlm.nih.gov
Methods Data of 920 male patients with PC enrolled in 9 prospective studies using
testosterone serum concentrations as primary endpoint were pooled. Patients aged 42–96 …

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

J Breul, E Lundström, D Purcea, WP Venetz, P Cabri… - 2017 - pubmed.ncbi.nlm.nih.gov
Introduction Androgen deprivation therapy (ADT) is a mainstay of treatment against
advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone …

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.

J Breul, E Lundström, D Purcea, WP Venetz… - Advances in …, 2016 - europepmc.org
Methods Data of 920 male patients with PC enrolled in 9 prospective studies using
testosterone serum concentrations as primary endpoint were pooled. Patients aged 42-96 …